Our Objective

 

LYV is a company dedicated to women’s health and comfort and has produced products to maintain a healthy vagina at any age, for any woman. Treatment of atrophic vaginitis has to date been limited to hormone preparations, hyaluronic acid gel and humectants.

 

 

There is a restricted range of treatments available for this common and problematic condition, with readily available over the counter remedies including moisturizing and lubricating gels, and prescription treatments involving steroid hormones. The former have limited efficacy and no real curative powers, and the latter are surrounded in controversy of public opinion.

 

 

Many women therefore remain untreated with this difficult condition. (1, 2, 39.) Fear of hormones is possibly the main reason for this, some of it justified, as there is a large group of women who are disallowed from using systemic hormone replacement treatment due to risk of cancer or past cancer.

 

 

Atrophic vaginitis can cause pain, discomfort, and sexual dysfunction with concomitant damage to relationships.

Thinning of the mucosa and change to the vaginal pH induced by estrogen deficiency predispose the urogenital tract to infection and mechanical weakness. (18.) Treatment with oestrogen is often effective but this is not an appropriate treatment for a large group of women, nor a desired treatment for those concerned about the potentially deleterious effects of exogenous hormones.

 

 

Up to 40% of post menopausal women suffer symptoms of atrophic vaginitis including decreased lubrication, fragile mucosa which can tear or become inflamed, irritation which extends to the urethra, frequent infections and reduction in pelvic support and continence. (1, 18, 19.) Hyaluronic acid has been shown to be helpful in alleviating the symptoms of vulvovaginal atrophy (1, 5, 16) while simple humectants have not been shown to help. (42.) Our company is committed to providing non hormonal vaginal products that relieve these symptoms.

 

 

About Us

 

LYV was established by Dee Vautier and Kit Hoffman in response to a need in the community that was not being appropriately addressed.

 

Both Dee and Kit have over 30 years experience in the medical industry, and both are passionate about improving the health and comfort of women who have found vaginal symptoms affect their lifestyle.

 

 

References

 

 

1. Mehta A, Bachmann G (2008) Vulvovaginal complaints. Clin Obstet Gynecol 51(3):549–555

 

2. Notelovitz M (1997) Urogenital aging: solutions in clinical practice.Int J Gynaecol Obstet 59:S35–S39

 

5. Tea MKM, Priemer V, Kubista E (2006) Aktuelles: Wirksamkeit und Sicherheit von Hyaluron-Säure-Zäpfchen (Cikatridina(R)) bei der Behandlung hormon-oder chemotherapieinduzierter vaginaler Atrophie bei Mammakarzinompatientinnen Journal für Fertilität und Reproduktion 16 (2) (Ausgabe für Österreich), pp 17–19

 

16. Morali G, Polatti F, Metelitsa EN, Mascarucci P, Magnani P, Marrè GB (2006) Open, non-controlled clinical studies to assess the efficacy and safety of a medical device in form of gel topically and intravaginally used in postmenopausal women with genital atrophy. Arzneimittelforschung 56(3):230–238

 

18. Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. American Family Physician 2000;61(May (10)):3090–6.

Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. New England Journal of Medicine 1993;329(September (11)):753–6.

 

19. Avis NE, Brockwell S, Randolph Jr JF, et al. Longitudinal changes in sexual functioning as women transition through menopause: results from the study of women’s health across the nation. Menopause 2009;16(May–June (3)):442–52.

 

39. Antoine C, Ameye L, Paesmans M, Rozenberg S . 2014. Treatment of climacteric symptoms in breast cancer patients: A retrospective study from a medication databank . Maturitas 78 : 228 – 232 .

 

 

42. Nicoletta Biglia, Elisa Peano, Paola Sgandurra, Giulia Moggio, Enrico Panuccio, Marco Migliardi, Nicoletta Ravarino, Riccardo Ponzone & Piero Sismondi (2010) Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study, Gynecological Endocrinology, 26:6, 404-412, DOI:10.3109/09513591003632258